Extending Telomere Length with a Multivitamin: A Pilot Study

Eugene J Bruno1, Graham D Simpson2 and Robert L Martin2

1Huntington College of Health Sciences, Knoxville, TN 37918, USA
2West-Martin Longevity, USA

*Corresponding author: Eugene J Bruno, MS, MHS, RH (AHG), Professor of Nutraceutical Science and Provost, Huntington College of Health Sciences, Knoxville, TN 37918, USA, E-mail: gbruno@hchs.edu

Received date: November 03, 2017; Accepted date: November 09, 2017; Published date: November 15, 2017

Abstract

Context: Although telomeres are “sacrificial” DNA without any necessary genetic content, each time a cell divides, telomeres get shorter. When they decrease to a critical length, cell division ceases and cells becomes inactive or “senescent” or die. This process is associated with aging. To some extent, the process of telomere shortening is slowed by the enzyme telomerase, whose purpose it is to add telomere length to DNA. Certain nutraceuticals have been shown to activate telomerase, and extend telomere length. While this will not make cells immortal, it may extend their lifespan.

Objectives: The study intended to examine the effectiveness of a multivitamin formulated to extend telomere length, and ascertain the viability of conducting a larger, randomized, controlled trial in the future.

Design: The study a 90-day, open-label pilot.

Participants: Generally healthy men and women older than 18 years.

Intervention: All subjects received a 90-day supply of the multivitamin, and were instructed to take one table three times daily with meals.

Outcome measures: The endpoint was absolute telomere length, measured with the quantitative real-time polymerase chain reaction (qPCR) method, using a DNA sample from a buccal (inner-cheek) swab of each subject.

Results: 10 subjects completed the protocol. 8 of the 10 had notable increases in telomere length. The mean increase in telomere length for all subjects was 55.86%.

Conclusions: The current pilot trial demonstrated the efficacy of the multivitamin in lengthening the telomeres. These findings suggest that it is worthwhile to conduct a larger, randomized, controlled trial to measure the telomere lengthening effects of the multivitamin formula.

Keywords: Nutraceuticals; Genetic; Multivitamin; Buccal; Telomeres

Introduction

There are multiple theories on aging which may be classified under the general headings of programmed aging or unprogrammed aging. Programmed aging may be described as aging resulting from genetically programmed factors. Unprogrammed aging may be described as aging resulting from molecular damage to normal body cells and molecules. According to Spence [1], a compelling argument can be made for some manner of programmed aging since aging begins at birth and each species seems to have its own average lifespan. The telomere theory of aging falls into this classification.

As cells age, they lose a certain number of base pairs of DNA, known as telomeres, from the end of each chromosome every time cell division takes place. Although the telomeres are “sacrificial” DNA without any necessary genetic content, there is still a problem. When these telomeres have decreased to a critical length, cell division ceases; although cell senescence may continue for a time [2]. This finite ability to replicate is known as the “Hayflick limit,” and has been seen in normal cultured human and animal cells [3]. Fibroblast cells taken from adults would only divide about 20 times in vitro, although this limit is rarely, if ever, reached in the body [1]. Summarily, each time a cell divides, telomeres get shorter. When they get too short, the cell can no longer divide and becomes inactive or “senescent” or dies. This process is associated with aging [2].

To some extent, the process of telomere shortening is slowed by the enzyme telomerase, whose purpose it is to add telomere length to DNA [2]. Telomerase is found in some cells (e.g., germ cells and stem cells), which must divide continually to perform their functions. By promoting telomerase activity, it is possible to increase telomere length and consequently extend the period of time that cellular division can take place. While this will not make cells immortal, it may extend their lifespan [3].

Of particular interest is the fact that certain nutraceuticals have been shown to activate telomerase, and extend telomere length. One
such nutraceutical is vitamin D. In a double blind, randomized and placebo-controlled clinical trial [4], Zhu et al. examined the effect of vitamin D supplementation on telomerase activity in 37 overweight African American adults. Subjects received a placebo or the equivalent of 2000 IU oral vitamin D3 supplementation daily for 16 weeks. Results showed that in the vitamin D group, telomerase activity significantly increased by 19.2% (P<0.0001). The significance persisted after controlling for age, sex and body mass index. Telomerase activity in the placebo group did not change.

This is consistent with research [5] by Richards et al. which showed that higher serum vitamin D concentrations in 2160 women were positively significantly associated with leukocyte telomere length (P=0.001), and the difference in telomere length between those with the highest and lowest vitamin D intake was 107 base pairs, which is equivalent to 5 years of telomeric aging. Similarly, human research has demonstrated longer telomere length in association with higher consumption of tea [6], lutein, zeaxanthin, and vitamin C [7], as well as several other vitamins and minerals [8].

As a result of these, and other studies demonstrating the telomerase activating and/or telomere lengthening effects of nutraceuticals, a multivitamin was formulated to extend telomere length (TeloVite, West-Martin Longevity) and a pilot study was conducted to examine the efficacy of the formulation in extending telomere length, and ascertain the viability of conducting a larger, randomized, controlled trial in the future.

Materials and Methods

Participants

The 90-day study was an open-label pilot. Generally healthy men and women older than 18 years were deemed eligible for participation. Subjects were recruited between February 1, 2013, and June 1, 2013, from a video solicitation on the website of West-Martin Longevity. All eligible patients were screened by the principal investigator. All volunteers had to have stable health (i.e., no hospitalizations, medical procedures, or changes in medications for at least 30 d prior to enrollment). Exclusion criteria included (1) having a life expectancy of less than 6 months, (2) being pregnant or currently breastfeeding, (3) being unwilling or unable to complete 90-days of supplementation with Telovite, or (4) currently using any other dietary supplement.

Procedures

After written informed consent was obtained, baseline assessments were completed, including each participant’s (1) demographics; (2) medical history; (3) current medications and dosages; (4) height; (5) weight; and (6) BMI. Subjects received individualized instructions regarding the use of Telovite. DNA samples from buccal swabs were obtained at baseline, and at day 90.

Intervention

All subjects received a 90-day supply of Telovite (Table 1), and were instructed to take one tablet, three times daily with meals. They were also instructed not to change their current dietary practices or exercise routine.

<table>
<thead>
<tr>
<th>Amount Per 3 Tablets:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamin A (as acetate, beta-carotene)</td>
<td>5000 IU</td>
</tr>
<tr>
<td>Vitamin C (as ascorbic acid, calcium ascorbate)</td>
<td>400 mg</td>
</tr>
<tr>
<td>Vitamin D3 (as cholecalciferol)</td>
<td>2000 IU</td>
</tr>
<tr>
<td>Vitamin E (as d-alpha tocopheryl succinate and mixed tocopherols)</td>
<td>30 IU</td>
</tr>
<tr>
<td>Vitamin K2 (as MK7)</td>
<td>45 mcg</td>
</tr>
<tr>
<td>Vitamin B1 (as thiamin HCI)</td>
<td>50 mcg</td>
</tr>
<tr>
<td>Vitamin B2 (riboflavin)</td>
<td>50 mcg</td>
</tr>
<tr>
<td>Niacin (as Niacinamide)</td>
<td>100 mcg</td>
</tr>
<tr>
<td>Vitamin B6 (as pyridoxine HCI)</td>
<td>50 mcg</td>
</tr>
<tr>
<td>Folic acid</td>
<td>400 mcg</td>
</tr>
<tr>
<td>Vitamin B12 (as cyanocobalamin)</td>
<td>100 mcg</td>
</tr>
<tr>
<td>Biotin</td>
<td>300 mcg</td>
</tr>
<tr>
<td>Pantothenic Acid (as d-calcium pantothenate)</td>
<td>50 mg</td>
</tr>
<tr>
<td>Calcium (as carbonate, dbasic calcium phosphate, citrate, ascorbate)</td>
<td>220 mg</td>
</tr>
<tr>
<td>Phosphorus (as dbasic calcium phosphate)</td>
<td>48 mg</td>
</tr>
<tr>
<td>Iodine (potassium iodide, kelp)</td>
<td>150 mcg</td>
</tr>
<tr>
<td>Magnesium (as oxide, citrate)</td>
<td>100 mg</td>
</tr>
<tr>
<td>Zinc (as amino acid chelates)</td>
<td>15 mg</td>
</tr>
<tr>
<td>Selenium (as selenomethionine)</td>
<td>70 mcg</td>
</tr>
<tr>
<td>Copper (as amino acid chelates)</td>
<td>2 mg</td>
</tr>
<tr>
<td>Manganese (as amino acid chelates)</td>
<td>2 mcg</td>
</tr>
<tr>
<td>Chromium (as polynicotinate)</td>
<td>150 mcg</td>
</tr>
<tr>
<td>Molybdenum (as sodium molybdate)</td>
<td>5 mcg</td>
</tr>
<tr>
<td>Chloride (as potassium chloride)</td>
<td>72 mcg</td>
</tr>
<tr>
<td>Potassium (as potassium chloride)</td>
<td>80 mg</td>
</tr>
<tr>
<td>Green Tea leaf extract (Standardized to 90% polyphenols)</td>
<td>250 mg</td>
</tr>
<tr>
<td>Chlorella (Chlorella vulgaris)</td>
<td>100 mg</td>
</tr>
<tr>
<td>L-Carnosine</td>
<td>50 mg</td>
</tr>
<tr>
<td>Resveratrol (providing 30 mg trans-resveratrol)</td>
<td>60 mg</td>
</tr>
<tr>
<td>Grape seed extract (85-95% OPC)</td>
<td>30 mg</td>
</tr>
<tr>
<td>Choline bitartrate</td>
<td>25 mg</td>
</tr>
<tr>
<td>Inositol</td>
<td>25 mg</td>
</tr>
<tr>
<td>Silicon (as sodium metasilicate)</td>
<td>2 mg</td>
</tr>
<tr>
<td>Lycopene</td>
<td>300 mcg</td>
</tr>
<tr>
<td>Lutein</td>
<td>250 mcg</td>
</tr>
</tbody>
</table>
Zeaxanthin 50 mcg
Boron 150 mcg
Vanadium (as vanadyl sulfate) 10 mcg
Nickel (as nickel sulfate) 5 mcg

Table 1: Telovite Composition.

Outcomes
The outcome was absolute telomere length, measured with a simple and reproducible, quantitative real-time polymerase chain reaction (qPCR) method described by O’Callaghan and Fenech, using a DNA sample from a buccal (inner-cheek) swab of each subject [9]. The qPCR analysis was conducted at Titanovo Labs (North Carolina).

Fifteen subjects were recruited for the pilot study. Due to attrition and non-compliance, ten subjects completed the protocol and were included in the results. Results were that 8 out of the 10 subjects had notable increases in telomere length, whereas the remaining two subjects had a decrease in telomere length. The reason for the decrease in telomere length in the 2 subjects is unclear (Table 2).

Table 2: Change in Telomere Length from 90 Days Supplementation with Telovite.

<table>
<thead>
<tr>
<th>Subject</th>
<th>Sex</th>
<th>Age</th>
<th>Telomere Length-Day 0</th>
<th>Telomere Length-Day 90</th>
<th>Change in Telomere Length</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>50</td>
<td>0.9</td>
<td>1.8</td>
<td>0.9</td>
<td>100</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>53</td>
<td>1.3</td>
<td>2</td>
<td>0.7</td>
<td>52.38</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>44</td>
<td>1</td>
<td>1.7</td>
<td>0.7</td>
<td>67.6</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>51</td>
<td>1.1</td>
<td>1.8</td>
<td>0.7</td>
<td>63.45</td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>62</td>
<td>0.8</td>
<td>1.6</td>
<td>0.8</td>
<td>100</td>
</tr>
<tr>
<td>6</td>
<td>F</td>
<td>69</td>
<td>1.1</td>
<td>1.5</td>
<td>0.4</td>
<td>35</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>72</td>
<td>0.9</td>
<td>1.8</td>
<td>0.9</td>
<td>99.11</td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>71</td>
<td>0.8</td>
<td>1.6</td>
<td>0.8</td>
<td>100.5</td>
</tr>
<tr>
<td>9</td>
<td>M</td>
<td>49</td>
<td>1.5</td>
<td>1.1</td>
<td>-0.4</td>
<td>-26.13</td>
</tr>
<tr>
<td>10</td>
<td>F</td>
<td>49</td>
<td>0.9</td>
<td>0.6</td>
<td>-0.3</td>
<td>-33.33</td>
</tr>
</tbody>
</table>

The mean increase in telomere length for the eight subjects was 77.26%. When all 10 subjects are included, the mean increase in telomere length was 55.86%.

Discussion
The purpose of this pilot study was to examine the efficacy of the Telovite formulation in extending telomere length, and ascertain the viability of conducting a larger, randomized, controlled trial in the future. While there were an insufficient number of subjects to adequately power the study and calculate statistical significance, the results of this open-label pilot study are promising, and indicate that 90 days of supplementation with Telovite was effective in lengthening telomeres in the majority of subjects tested.

Conclusion
The current pilot trial demonstrated the efficacy of Telovite in lengthening the telomeres of 8 out of the 10 subjects. These findings suggest that it is worthwhile to conduct a larger, randomized, controlled trial to measure the telomere lengthening effects of Telovite, giving further consideration to the reasons behind the lack of telomere lengthening in the minority of subjects.

Acknowledgement
This study was made possible by a grant from West-Martin Longevity.

References